The specter of generic rivalry has consistently loomed above copyright’s iconic drug, Viagra, raising questions about the outlook of similar pharmaceutical ventures. While first periods saw significant returns, the exclusivity expiration has opened the path for less expensive substitutes, potentially reducing revenue and creating a real risk for… Read More